Abstract: Objective : To investigate the clinical value of detecting serum levels of CEA, CA-153, ICAM-1, and E-se-lectin for patients with breast carcinoma. Methods : Using chemiluminescent immunoassay, we detected theserum levels of CEA, CA-153, ICAM-1 and E-selectin in 130 patients with breast cancer, 30 patients with be-nign breast tumors and 30 healthy control subjects. Results : The serum levels of CEA, CA-153, ICAM-1, andE-selectin in the breast cancer group were significantly higher than those in the benign breast disease groupand the control group (P<0.01). In the breast cancer group, the levels of these tumor markers were increasedas the malignant degree increased and were remarkably higher in patients with metastasis ( P <0.01). The com-bined detection of these four markers had a higher sensitivity than the independent detection of each marker.The sensitivity of combined detection of CA-153 and E-selectin was the most sensitive. Conclusion : E-se-lectin, ICAM-1, CEA, and CA-153 are important tumor markers of breast cancer and may play a significantrole in the development and metastasis of breast cancer. E-selectin, ICAM-1, CEA, and CA-153 can be usedas tumor markers in the diagnosis of breast cancer and may be of great value in assessing patient conditionand predicting prognosis.